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Abstract
Mitochondrial outer membrane permeabilization (MOMP) is one of the most important points, in majority of apoptotic signaling
cascades. Decision mechanism controlling whether the MOMP occurs or not, is formed by an interplay between members of
the Bcl-2 family. To understand the role of individual members of this family within the MOMP regulation, we constructed a
boolean network-based mathematical model of interactions between the Bcl-2 proteins. Results of computational simulations
reveal the existence of the potentially malign configurations of activities of the Bcl-2 proteins, blocking the occurrence of MOMP,
independently of the incoming stimuli. Our results suggest role of the antiapoptotic protein Mcl-1 in relation to these configurations.
We demonstrate here, the importance of the Bid and Bim according to activation of effectors Bax and Bak, and the irreversibility
of this activation. The model further shows the distinct requirements for effectors activation, where the antiapoptic protein Bcl-w is
seemingly a key factor preventing the Bax activation. We believe that this work may help to describe the functioning of the Bcl-2
regulation of MOMP better, and hopefully provide some contribution regarding the anti-cancer drug development research.
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1. Introduction
Apoptosis is a process of programmed cellular death, distinct
from necrosis [1, 2], which can be well distinguished by its
morphology [3]. It is an important homeostatic mechanism, de-
fects of which may cause variety of serious diseases, including
the neurodegenerative disorders [4], autoimmune diseases [5],
or even a cancer [6, 7, 8]. Signals leading to an apoptosis initia-
tion can originate from an extracellular environment or from
a cell’s internal space [9, 8]. Apoptotic signals further pro-
ceed through an apoptotic signaling and regulatory network,
that contains several control points [9, 8]. One, highly im-
portant of such points is formed by a family of Bcl-2 (B-cell
lymphoma 2) proteins [10, 11]. An interplay between the Bcl-2
family’s members controls one of the most crucial apoptotic
events - the mitochondrial outer membrane permeabilization
(MOMP) [12, 13].
MOMP allows release of apoptotic key players -
Smac/DIABLO and a cytochrome c, from a mitochon-
drial intermebrane space to a cytosol [12, 13]. In presence of
ATP, released cytochrome c binds to a cytosolic protein Apaf-
1, causing Apaf-1 oligomerization and a recruitment of an
inactive pro-caspase-9, leading to formation of a multi-protein
complex known as an apoptosome [14, 15, 16]. Within the
apoptosome, pro-caspase-9 subsequently undergoes processing
and activation [14, 15, 16]. The active caspase-9 proteolytically
activates caspase-3 [17]. Smac/DIABLO, once released to
the cytosol, inhibits XIAP (X-linked inhibitor of apoptosis)
- the most prominent suppressor of caspases -3 and -9 [18].
Caspase-3 and other effector caspases (caspases -6 and -7) are
the primary executioners of the apoptosis [19, 8]. Activation
of these makes the point of no-return, after which apoptosis
irreversibly occurs [20]. Although, mitochondria-independent
apoptotic signaling pathways are currently well known [21],
the mitochondrial (also known as intrinsic) pathway currently
remains to be considered as the major one [22].
The Bcl-2 family mediated control of MOMP is carried in
”all or nothing” manner, giving no possibility of intermediate
MOMP. A mechanism of controlling such a decision resembles
what a complex systems science describes as a bistable switch.
Currently the steady-state bistability is considered as the most
suitable framework for a description of the apoptosis control.
This interesting system properties have made Bcl-2 family an
attractive subject of a mathematical modeling and computer
simulations. There are several works regarding a modeling and
a simulation of the Bcl-2 family and the control of MOMP, re-
vealing and examining a variety of non-linear system behaviors
such as robustness, stimulus-response ultrasensitivity [23] and
bistability [24, 25, 26]. Besides these, Bcl-2 family was in-
volved in several other, more general models of apoptosis sig-
naling [27, 28, 29].
All the above-mentioned models were utilized to dynami-
cally simulate the chemical reaction kinetics of the studied bio-
logical system. Complexity of such models is often reduced
by grouping of several functionally similar species together.
Moreover, the most prominent group’s member is taken as the
model’s representation of the whole group of species. Although
previous models of Bcl-2 regulatory network are on the vari-
ous levels of details, they all adopt such simplification. This
is done usually by grouping the Bcl-2 family’s members into
three groups according to their structural and functional clas-
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sification. Such division provides reasonable trade-off between
model’s simplicity and plausibility. However, when grouped to-
gether, certain important functional specificities of Bcl-2 fam-
ily’s individuals are ignored.
The critical limitation in the development of the detailed,
quantitative model of the Bcl-2 family is the absence of biolog-
ical data. The identification of the quantitative parameters (e. g.
reaction rates and/or physiological concentrations of species) is
dependent on the relevant experimental in vivo measurements,
which are still a systems biology bottle neck [30]. In absence
of quantitative data, such detailed models of Bcl-2 family must
be limited to a qualitative manner.
In this work we provide a qualitative model of the Bcl-2
family mediated regulation of MOMP based on the Boolean
network modeling. The boolean network (BN) approach is
one of the most suited to a qualitative modeling of complex
biological systems, even with a limited biological knowledge
[30, 31]. BN, first introduced in the late 1960s [32], has been
originally used to model gene regulatory networks and signal-
ing pathways [33]. Although, BN does not model dynamics of
the studied system, it may reveal and examine many interesting
complex-system properties [33]. The certain members of the
Bcl-2 family appeared for the first time in BN-based model in
work of Calzolari et al [34], involved in the model of an apop-
tosis gene network. Mai and Liu [31] and few months later
Schlatter et al [30], published currently the most recent BN-
based models of apoptosis, both containing simplified mecha-
nism of Bcl-2 family MOMP control. However, as far as we
know, there haven’t been published any BN-based model, fo-
cused solely on the Bcl-2 family.
2. Materials and methods
2.1. Model’s structure and its biological relevance
Bcl-2 family’s members are functionally classified as either
antiapoptotic, or proapoptotic. Structurally, Bcl-2 proteins can
be categorized according to the number of Bcl-2 homology
domains (BH) in their α-helical regions [35, 8]. Antiapop-
totic members (Mcl-1, A1, Bcl-xL, Bcl-2, Bcl-w and Bcl-B)
are characterized by the presence of four BH domains (BH1-
4) [36, 37]. Their role is to prevent MOMP by inhibition of
proapoptotic family members [36, 37]. Proapoptotic members
can be divided to BH3-only proteins and multidomain proteins
- effectors [8]. BH3-only proteins can be further subdivided
based upon their role in apoptotic signaling. BH3-only sub-
group members, termed sensitizers (Noxa, Bad, Puma, Hrk,
Bmf and Bik), can only bind to antiapoptotic Bcl-2 proteins,
forming inactive dimers [35]. Members of another BH3 sub-
group, termed activators (Bim and Bid), can act in the same
way [35], but in addition, activators can directly activate effec-
tors [36, 38]. Effectors, once activated, undergo oligomeriza-
tion and form pores in mitochondrial outer membrane (MOM),
leading eventually to MOMP. [39, 13]. Therefore, effectors
are primary target of inhibition by their antiapoptotic relatives
[38].
Altogether, interactions between Bcl-2 family members can
be classified into only three types: i) Binding and mutual inhibi-
tion between antiapoptotic and BH3-only proteins. ii) Binding
and mutual inhibition between antiapoptotic proteins and effec-
tors. iii) Activation of effectors by BH3 only proteins. How-
ever, the situation ceases be so simple when we focus on the
interaction between individual molecules. E.g., the BH3 only
sensitizer Noxa can bind to and inhibit only two antiapoptotic
proteins (see Table 1) [40, 35, 8], but the other BH3 only sen-
sitizer, Puma is able to inhibit five of six major antiapoptotic
proteins [40, 35, 8]. On the other hand, while it seems that
antiapoptotic protein Bcl-B is not bound and inhibited by any
of the BH3 only proteins [41], the other anti-apoptotic pro-
tein Bcl-xL is bound by seven of them [40, 8]. There is also
a strong asymmetry in the level of inhibition of effectors by
antiapoptotic proteins. While Bak is inhibited only by three an-
tiapoptotic proteins, Bax is inhibited by all six of them [35, 8].
Knowledge about interaction between Bcl-2 family’s mem-
bers, was translated to the boolean-based model we present
here. The model contains 14 nodes, representing the Bcl-2 fam-
ily’s members. Each member of the Bcl-2 family is represented
by one of the model’s nodes. Except of the proteins Bad and
Bmf that are coupled together and represented by a single node,
and similarly the proteins Hrk and Bik. The proteins that were
coupled together, share the same intra-familiar interaction pro-
files (see Table 1). The model contains 34 connection between
nodes, each representing one molecular interaction.
2.2. Transition rules
In a given time, each of the model’s nodes can be in either
the active or inactive state. Each of the nodes is affected by
received inputs from one or several other upstream nodes. The
state of the node i in the next time step si(t + 1) is defined by
the following transition rule:
si(t + 1) = ∆
(
ei +
∑
j
ri j s j(t)
)
, (1)
∆(x) =

1 , x > 0,
si(t) , x = 0,
0 , x < 0
(2)
Here, ri j specifies the relation of the j-th node to i-th node, and
may have three possible values: ri j = 1 if j-th node activates
i-th node, ri j = −1 if j-th node inhibits i-th node and ri j = 0, if
nodes j and i are not connected (the relationships between each
of the model’s nodes are depicted in the Figure 1). The value
of ei defines the expression of the protein represented by the i-
th node (see Section 2.3). Since Bcl-2 family members inhibit
each other by mutual binding and formation of inactive dimers,
our model treats the inhibitory relationships between two nodes
as bipartite (if ri j = −1, then r ji = −1).
During the model’s simulation, the states of all nodes are
step-wise simultaneously reevaluated according to the transi-
tion rule described by the eq. (1), until the simulation is termi-
nated (see 2.4).
2
Bcl-2 Bcl-2 Full name of the protein Binds to and inhibits Ref.
family class family member
Antiapoptotic
members:
Mcl-1 Myeloid cell leukemia sequence-1 Noxa, Bim, Puma, Bax, Bak [40, 8]
Bcl-2 B-cell lymphoma 2 Bad, Bim, Puma, Bmf, Bax [40, 8]
A1 Bcl-2 related protein Noxa, Bim, Puma, Bid, Hrk, Bik, Bax, Bak [40, 8]
Bcl-xL Bcl-2-like Bad, Bim, Puma, Bid, Hrk, Bmf, Bik, Bak, Bax [40, 8]
Bcl-w Bcl-2-like-2 Bad, Bim, Puma, Bid, Hrk, Bmf, Bik, Bax [40, 8]
Bcl-B Bcl-2-like-10 Bax [41]
BH3-only
members:
Noxa Phorbol-12-myristate-13-acetate-induced protein 1 Mcl-1, A1 [40, 35, 8]
Bad Bcl-2 antagonist of cell death Bcl-xL, Bcl-w, Bcl-2 [40, 35, 8]
Bim Bcl-2like-11 Bcl-xL, Bcl-w, Bcl-2, Mcl-1, A1 [40, 35, 8]
Puma Bcl-2-binding component-3 Bcl-xL, Bcl-w, Bcl-2, Mcl-1, A1 [40, 35, 8]
tBid truncated BH3-interacting domain death agonist Bcl-xL, Bcl-w, A1 [40, 35]
Hrk Harakiri Bcl-xL, Bcl-w, A1 [40]
Bmf Bcl-2-modifying factor Bcl-xL, Bcl-w, Bcl-2 [40, 35]
Bik Bcl-2-interacting killer Bcl-xL, Bcl-w, A1 [40]
Effectors:
Bak Bcl-2-antagonist/killer-1 Bcl-xL, Mcl-1, A1 [35, 8]
Bax Bcl-2-associated X protein Bcl-xL, Bcl-w, Bcl-2, Bcl-B, Mcl-1, A1 [35, 8]
Table 1: Binding and inhibition between individual members of the Bcl-2 family.
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Figure 1: Relationships between nodes of the model. The red squares represent
the negative relationships of the inputs toward the related nodes. Negative re-
lationship corresponds to mutual binding and inhibition bewteen two members
of the Bcl-2 family (see Table 1). The blue squares represent the positive rela-
tionships of the inputs toward the related nodes. Positive relation corresponds
to activation of the effectors Bax/Bak by certain BH3 only proteins - activators
(tBid, Bim) [36, 37].
2.3. Influence of the external conditions
The transition function of the i-th node is dependent on the
value of ei. The value of vector E (E = {e1, e2, . . . e16}) repre-
sents here, what we termed the ”expression” of the the Bcl-2
family proteins. The value ei = 1, corresponds to the cellu-
lar conditions allowing the synthesis and, if required, the post-
translational/post-transcriptional activation (e. g. activation of
Bid requires proteolytic cleavage by Caspase-8 [42]) of the i-
th protein. Alternatively, the value ei = 0, corresponds to the
conditions preventing the synthesis and/or post-translations ac-
tivation of the i-th protein.
Since the model contains 14 nodes, the vector of expressions
could have 214 = 16384 of possible values. However, since
other than BH3-only mediated activation of Bax/Bak is irrel-
evant in our work (the subject of our study is the Bcl-2 family
mediated regulation of MOMP), we exclude here the expression
vectors where eBax = 1 or eBak = 1, reducing thus the number
of possible values to 212 = 4096. The value of the vector E
remains constant during each simulation span.
2.4. Model’s ending states
The simulation is terminated in the time t if state of the model
S (S = {s1, s2, . . . s14}) is satisfying the following condition:
S (t) = S (t − n) , n = 1, 2, . . . 14 (3)
The condition described in the eq. (3), can imply either that
the model converged to the steady-state (n = 1), the model is
oscillating between two different states (n = 2), or the model is
periodically orbiting through the set of states (n > 2).
The state S (t), satisfying the condition (3) is the model’s end-
ing state S (tend). If the S (tend) involves the states of both effec-
tors, s(tend)Bax = 0 and s(tend)Bak = 0, then the S (tend) is denoted
as the ”survival” state. If the S (tend) involves the states of one of
the effectors, s(tend)Bax = 1, or s(tend)Bak = 1, then the S (tend)
is simply denoted as the ”pro-momp” state.
3
3. Results
3.1. We have revealed 1046 of the ”survival” states, in which
the model can persist while the effectors Bak and Bax re-
main inactive.
The very first step, in order to investigate the properties of the
model, was to find the ending states in which model is allowed
to persist without the activation of effectors (Bak and Bax) -
survival states (see 2.4).
Therefore, for each of the 4096 expression vectors (see 2.3)
we performed, 4096 simulations spans, each span starting from
one of the 16384 of the initial states (16384 = 214, that is the
number of possible initial states).
We have identified 1046 of the unique survival states. The
388 of these states are logical steady-states, remaining 678 of
the survival states are oscillating. Hereafter, we assume that
under normal cellular conditions the Bcl-2 regulatory mecha-
nism can persist only within one of these 1046 states. In any
of these states, the model may persist only under certain ex-
pression vectors. As we change the expressions, the model may
relocate from the given survival state to the opposite one.
In the next step, we have investigated the transitions from the
survival states to other ending states. To analyze this transitions,
for each of the 1046 of the survival states, we have performed
4096 simulation spans, each span using one of the expression
vectors. For each simulation, the given survival state has been
used as the initial state of the model.
Around 70% of the 4.2 millions (1046×4096) of simulations
led to survival, remaining 30% of the simulations led to pro-
momp ending states, where at least one of the effectors was
found active.
3.2. We discovered 200 of the ”tumor” states – once accessed
by the model, the model remains trapped, unable to turn
out, to any functionally distinct state.
During the analysis of the transitions between the survival
states and the pro-momp states, we have revealed interesting
finding. We have discovered, the existence of 200 survival
states, from which the model is unable to be turned to pro-
momp states, regardless of the vector of expressions. More-
over, the model, once located in such a ”trapping” state, can
only be turned to other trapping state. The trapping of the Bcl-2
regulatory mechanism in one of these states, would cause fatal
malfunctioning of the momp regulation, that could possibly re-
sult in a tumorgenesis. Therefore, we denoted these states as
the ”tumor” states.
These states (see the black squares in the Fig 2, top) can be
characterized by strong imbalance in activity of antiapoptotic
vs BH3-only proteins. The tumor states are especially abundant
among the survival states involving the activity of Mcl-1. Al-
though the activity of Mcl-1 is not necessary, nor sufficient con-
dition to classify a given model’s state as tumor state, it seems
that Mcl-1 plays a certain role here.
3.3. There are two functionally distinct subsets of survival
states. Those which allow model to activate the Bak, but
not Bax and the states allowing activation of both effec-
tors.
Remaining 846 survival states, can further be classified in
two groups. From the 54 survival states of the first group, model
can relocate only to pro-momp states where the only active ef-
fector is Bak. From the 792 survival states of the second group,
model can be turned to states with a single effector (Bak) activ-
ity, as well as to the pro-momp states, where both effectors are
active. While, the first group we denoted as ”semioptimal” (the
light green squares in Fig 2, top), the second one we denoted as
”optimal” (the dark green squares in Fig 2, top).
Similarly, we may distinguish several functionally distinct
subsets among the pro-momp states. Firstly, the every pro-
momp state may be classified according to the activity of effec-
tors. We have found 108 of the pro-momp states, in which, the
Bak is being active, but Bax remains inactive (the blue squares
in Fig 2, bottom). Besides these, we also have found 132 of the
pro-momp states, in which both effectors are being active (the
red squares in Fig 2, bottom). However, we haven’t found any
such ending state, where the Bax was active, while the Bak not,
indicating that such state is unaccessible by the model, regard-
less of expressions or initial conditions.
Secondly, the first of the mentioned groups – Bak-active only,
can further be divided in two functionally distinct subgroups:
states which allow additional activation of Bax (the light blue
squares in Fig 2, bottom), and those which doesn’t (the dark
blue squares in Fig 2, bottom).
It is very interesting that, while the first subgroup is accessi-
ble only from the ”optimal” survival states, the second one, can
be accessed from both, ”optimal” and ”semioptimal” survival
states.
3.4. Survival to momp transition is irrevesible.
We have performed another series of simulations, repetitively
simulating the model under each of the expressions vectors,
while using the pro-momp states as the initial conditions. We
have found out that it is impossible to turn the model from any
of the pro-momp states back to the survival one, regardless of
the expressions.
3.5. The transitions from the survival to momp are caused by
expression changes of four distinct types.
When taking previous results together, we may distinguish
six distinct groups of model’s ending states. Where three of
these groups associate survival states, involving no effectors ac-
tivity, two of them associate pro-momp states, involving the ac-
tivity of Bak, but not Bax, and the one group associating the
states involving the activity of both effectors. Assuming that,
the occurrence of momp requires only the single effector acti-
vation, four types of survival-to-momp transitions can be dis-
tinguished (T1 – T4, see Fig 3).
By calculation of the coefficient of multiple correlation (for
more details see Appendix A) – R2, we have analyzed the in-
fluence of the expression of the given protein on the initiation
4
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
0
1
0
0
0
1
1
0
0
0
1
0
0
1
0
0
1
0
1
0
0
0
1
1
0
0
0
1
0
0
0
1
0
1
0
0
1
0
0
1
0
1
0
0
0
1
1
0
0
0
1
0
0
0
0
1
1
0
0
0
1
0
1
0
0
1
0
0
1
0
1
0
0
0
1
1
0
0
0
0
0
0
0
1
1
1
0
0
1
0
1
1
0
0
1
1
0
1
0
0
1
1
1
0
0
1
0
0
1
1
0
1
0
1
0
1
0
1
0
1
1
0
0
1
1
0
0
1
0
1
1
0
1
0
0
1
1
1
0
0
1
0
0
0
1
1
1
0
0
1
0
1
1
0
0
1
1
0
1
0
1
0
0
1
1
0
1
0
1
0
1
0
1
1
0
0
1
1
0
0
0
1
1
1
0
0
1
0
1
1
0
1
0
0
1
1
1
0
0
0
0
0
1
1
1
1
0
1
0
1
1
1
0
1
1
0
1
1
0
1
1
1
0
1
0
1
1
1
1
0
1
0
0
1
1
1
1
0
1
0
1
1
1
0
1
1
0
1
1
0
1
1
1
0
1
1
0
0
1
1
1
1
0
1
0
1
1
1
0
1
1
0
1
1
1
0
0
1
1
1
1
0
1
0
1
1
1
1
0
0
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0 0 0 0 0 0
0 0 0 0 0 1
0 0 0 0 1 0
0 0 0 1 0 0
0 0 1 0 0 0
0 1 0 0 0 0
1 0 0 0 0 0
0 0 0 0 1 1
0 0 0 1 0 1
0 0 0 1 1 0
0 0 1 0 0 1
0 0 1 0 1 0
0 0 1 1 0 0
0 1 0 0 0 1
0 1 0 0 1 0
0 1 0 1 0 0
0 1 1 0 0 0
1 0 0 0 0 1
1 0 0 0 1 0
1 0 0 1 0 0
1 0 1 0 0 0
1 1 0 0 0 0
0 0 0 1 1 1
0 0 1 0 1 1
0 0 1 1 0 1
0 0 1 1 1 0
0 1 0 0 1 1
0 1 0 1 0 1
0 1 0 1 1 0
0 1 1 0 0 1
0 1 1 0 1 0
0 1 1 1 0 0
1 0 0 0 1 1
1 0 0 1 0 1
1 0 0 1 1 0
1 0 1 0 0 1
1 0 1 0 1 0
1 0 1 1 0 0
1 1 0 0 0 1
1 1 0 0 1 0
1 1 0 1 0 0
1 1 1 0 0 0
0 0 1 1 1 1
0 1 0 1 1 1
0 1 1 0 1 1
0 1 1 1 0 1
0 1 1 1 1 0
1 0 0 1 1 1
1 0 1 0 1 1
1 0 1 1 0 1
1 0 1 1 1 0
1 1 0 0 1 1
1 1 0 1 0 1
1 1 0 1 1 0
1 1 1 0 0 1
1 1 1 0 1 0
1 1 1 1 0 0
0 1 1 1 1 1
1 0 1 1 1 1
1 1 0 1 1 1
1 1 1 0 1 1
1 1 1 1 0 1
1 1 1 1 1 0
1 1 1 1 1 1
s A
n
ti
a
p
o
p
to
ti
c
[M
cl
1,
A
1,
B
cl
X
l,
B
cl
−
2,
B
cl
−
w
,B
cl
−
B
]
sBak = 0, sBax = 0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
0
1
0
0
0
1
1
0
0
0
1
0
0
1
0
0
1
0
1
0
0
0
1
1
0
0
0
1
0
0
0
1
0
1
0
0
1
0
0
1
0
1
0
0
0
1
1
0
0
0
1
0
0
0
0
1
1
0
0
0
1
0
1
0
0
1
0
0
1
0
1
0
0
0
1
1
0
0
0
0
0
0
0
1
1
1
0
0
1
0
1
1
0
0
1
1
0
1
0
0
1
1
1
0
0
1
0
0
1
1
0
1
0
1
0
1
0
1
0
1
1
0
0
1
1
0
0
1
0
1
1
0
1
0
0
1
1
1
0
0
1
0
0
0
1
1
1
0
0
1
0
1
1
0
0
1
1
0
1
0
1
0
0
1
1
0
1
0
1
0
1
0
1
1
0
0
1
1
0
0
0
1
1
1
0
0
1
0
1
1
0
1
0
0
1
1
1
0
0
0
0
0
1
1
1
1
0
1
0
1
1
1
0
1
1
0
1
1
0
1
1
1
0
1
0
1
1
1
1
0
1
0
0
1
1
1
1
0
1
0
1
1
1
0
1
1
0
1
1
0
1
1
1
0
1
1
0
0
1
1
1
1
0
1
0
1
1
1
0
1
1
0
1
1
1
0
0
1
1
1
1
0
1
0
1
1
1
1
0
0
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
sBH3only [Noxa,Bad/Bmf,Bim, Puma, tBid,Hrk/Bik]
0 0 0 0 0 0
0 0 0 0 0 1
0 0 0 0 1 0
0 0 0 1 0 0
0 0 1 0 0 0
0 1 0 0 0 0
1 0 0 0 0 0
0 0 0 0 1 1
0 0 0 1 0 1
0 0 0 1 1 0
0 0 1 0 0 1
0 0 1 0 1 0
0 0 1 1 0 0
0 1 0 0 0 1
0 1 0 0 1 0
0 1 0 1 0 0
0 1 1 0 0 0
1 0 0 0 0 1
1 0 0 0 1 0
1 0 0 1 0 0
1 0 1 0 0 0
1 1 0 0 0 0
0 0 0 1 1 1
0 0 1 0 1 1
0 0 1 1 0 1
0 0 1 1 1 0
0 1 0 0 1 1
0 1 0 1 0 1
0 1 0 1 1 0
0 1 1 0 0 1
0 1 1 0 1 0
0 1 1 1 0 0
1 0 0 0 1 1
1 0 0 1 0 1
1 0 0 1 1 0
1 0 1 0 0 1
1 0 1 0 1 0
1 0 1 1 0 0
1 1 0 0 0 1
1 1 0 0 1 0
1 1 0 1 0 0
1 1 1 0 0 0
0 0 1 1 1 1
0 1 0 1 1 1
0 1 1 0 1 1
0 1 1 1 0 1
0 1 1 1 1 0
1 0 0 1 1 1
1 0 1 0 1 1
1 0 1 1 0 1
1 0 1 1 1 0
1 1 0 0 1 1
1 1 0 1 0 1
1 1 0 1 1 0
1 1 1 0 0 1
1 1 1 0 1 0
1 1 1 1 0 0
0 1 1 1 1 1
1 0 1 1 1 1
1 1 0 1 1 1
1 1 1 0 1 1
1 1 1 1 0 1
1 1 1 1 1 0
1 1 1 1 1 1
s A
n
ti
a
p
o
p
to
ti
c
[M
cl
1,
A
1,
B
cl
X
l,
B
cl
−
2,
B
cl
−
w
,B
cl
−
B
]
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Figure 2: Model’s ending states. The squares are depicting the ending states of
the model within the ”configuration space”, where the configurations of states
of nodes representing the Antiapoptotic and BH3-only proteins are arranged
along y- and x-axis, respectively. The figure on top, depicts the survival states –
Bax, Bax representing nodes are inactive. The black squares represent the ”tu-
mor” states, while the green squares represent the functionally ”semioptimal”
(light green) and ”optimal” (dark green) survival states. While the first men-
tioned, allow only the activation of Bak (transition T4 in Fig 3), but not Bax,
”optimal” states allow activation of both effectors. The figure at the bottom
depicts the non-survival states – either the Bax, or Bak is active (blue squares),
or both of them are active (red squares). The dark blue squares represent those
states, which allow subsequent activation of Bax, initiated by the change in the
expressions. In contrast, the states represented by the light blue squares suffer
from the inability to allow the activation of Bax.
T1
T2
T3
T4
sBak = 0, sBax = 0
sBak = 1, sBax = 0
sBak = 1, sBax = 1
Figure 3: Possible transitions between the individual subsets of model’s ending
states. Using the same color notation as in the Fig 2, the types of the model’s
transitions between five functionally distinct subgroups of model’s states are
depicted.
of these transitions. In addition to this, we also have studied the
importance of the individual proteins’ expression, to obtain the
picture about how these affect the momp initiation.
The results we have gained (see Fig 4) show that regardless
of the transition type, the continuous expression of at least one
of the activators (Bim, tBid) is, as expected, the key factor de-
termining whether the transition to momp occurs or not. On the
other hand it seems that the continuous expression of the Mcl-1
is the factor that prevents the momp at the most, compared to
expressions of other antiapoptotic proteins. It seems that the
statistical importance of the expression of activators and the ab-
sence of Mcl-1 is common for both T1 and T2. Nevertheless, the
transitions of type T2 - the activation of both effectors, addition-
ally relies on the lack of Bcl-B expression. This finding is not
surprisable as the Bcl-B is the model’s major inhibitor of Bax
that is not suppressed by any of the BH3-only proteins. Fur-
thermore, model predicts that after the transition of the type T1
drives the model to the Bak-active pro-momp state, subsequent
downregulation of Bcl-B could cause the additional activation
of Bax (the arrow pointing from the dark blue square to the red
one, Fig 3)
Transitions of the type T3 differs from previous types, since it
occurs in the presence of the Bcl-2 expression, exclusively. The
transitions of type T4 are caused by lack of the Mcl-1 expres-
sion while involve the tBid expression. However, the T4 type of
transitions may probably occur only rarely, since the number of
”semioptimal” states is very small compared to the number of
”optimal” ones.
Besides the survival-to-momp transitions we have been
interested about the causes of the transition from ”opti-
mal”/”semioptimal” to ”tumor” states. We have found (data
not shown) that the trapping of the model within the ”tumor”
state simply occurs as the anti-apoptotic expression dispropor-
tionately dominates over the expression of BH3-only proteins.
This points to the necessity of the balance between the presence
and synthesis of the both pro- and anti-apoptotic Bcl-2 proteins
within the cell.
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Figure 4: Multiple determination coefficients – R2 of the protein expressions
calculated across the sets of unique expressions vectors causing the survival-to-
momp transitions of given type (for more details see Appendix A).
4. Discussion
We have analyzed the Bcl-2 family interaction network using
the boolean network-based computational model. Bcl-2 family
members have been represented by model’s nodes, which ac-
tivity was binary encoded. The active (ON state) of the given
node represents the biologically active form of the represented
protein. Nodes are mutually interacting according to the given
transition rules, and pre-defined relationship matrix, represent-
ing the chemical interactions among the Bcl-2 proteins. In ad-
dition, the model behavior has been influenced by the vector
of expressions, that is representing the biological conditions,
change of which is the primary driving force of the Bcl-2 reg-
ulatory mechanism. The expression here is a mean to include
the post-translational and/or post-transcriptional activation of
zymogens, if relevant for given protein.
Computational simulations of the model, suggest that the
Bcl-2 family can withstand wide variety of signals control-
ling the activity of its pro- and anti-apoptotic members, with-
out causing the activation of Bax or Bak. While allowing the
cell survival, the Bcl-2 family may preserve in one of the many
different states. However, our results show, that once the anti-
apoptotic proteins significantly overwhelm the BH3-only pro-
teins’s activity, the Bcl-2 family regulation may be seriously
harmed. Our model predicts, that once this happens, even the
subsequent activation of pro-apoptotic BH3-only proteins, can-
not reverse the MOMP regulation malfunctioning. Moreover,
our results suggest that the presence of the anti-apoptotic pro-
tein Mcl-1 may play an important role here. However, the exis-
tence of such ”tumorgeneric” trap shows the importance of the
equilibrium, dynamically preserved by the continuous expres-
sion of both anti- and pro-apoptotic proteins.
According to our simulations, depending on the current state
of the Bcl-2 family, certain configurations of the incoming sig-
nals can cause state transition including the activation of effec-
tors Bak, and/or Bax. As the most important factors among
such signals are the activation of Bid (its truncation to tBid)
and/or the activation of Bim and the downregulation of Mcl-
1. It seems that the activation of Bak is much less stimuli-
demanding compared to the activation of Bax. However, it
seems that the activation of Bax strongly benefits from the Bcl-
w downregulation. Finally, our results confirm the irreversibil-
ity of the effectors activation.
Despite the limited predictive and explanatory power of the
boolean-based approach, we believe that the proposed model
sheds a light on the modus operandi of the Bcl-2 mediated reg-
ulation of momp. In future we would like to focus our attention
on the system properties of the same model, including its ro-
bustness and responsivity.
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Appendix A. Calculation of multiple determination coeffi-
cients
This analysis is proposed to compare the importance of the
presence/absence of particular proteins expression, regarding
the transition from certain group of states to another group of
states. Here we describe the methodology we used in these
analyses.
Let’s have set of n unique expression vectors – E =
{e1, e2, . . . e12} that cause the studied transition. For each couple
of nodes i, j we can calculate the phi coefficient:
φi j =
n11n00 − n10n01√
n1•n0•n•0n•1
, (A.1)
where n00, n01, n10, n11, are counts of the following combina-
tions of values ei, e j across the set of expression vectors:
ei = 1 ei = 0 total
e j = 1 n11 n10 n1•
e j = 0 n01 n00 n0•
total n•1 n•0 n
The phi coefficient is a measure of association for two binary
variables, similar to Pearson correlation coefficient.
The matrix of phi coefficients - Rφ, is then used as to calculate
the coefficient of multiple determination – R2:
R2i = c
T
i R
−1
φ,i ci, (A.2)
where the ci is the vector of values φi j, j = 1, 2 . . . 12, i , j. ci
is actually the vector of correlations between the independent
variables and the target variable – ei. cTi is the transpose of c.
The Rφ,i is the matrix Rφ, reduced by removing the i-th line and
i-th column. Rφ,i is actually the matrix of correlations between
the independent variables and R−1φ,i is the inverse of the matrix
Rφ,i.
Finally, the R2i was multiplied by −1 if the count of ei = 0
appearances greater than of the ei = 1, across the set of expres-
sions – the expression of the i-th node was mostly absent among
the expression vectors causing the given transition.
In the case that the values of i − th protein expression had no
variability – either ei = 0, or ei = 1 among all the expression
vectors, the R2i was arbitrary set either to −1, or 1, respectively.
The correlations of any of the other expression with the ei were
then excluded from any other calculations. Such situation oc-
curs in case of expression of Bcl-2 among the transitions of the
type T3 (see Fig 4)
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